Evaluation and discovery of blood-based biomarkers for ataxia
NINDS - National Institute of Neurological Disorders and Stroke
About This Grant
Summary Genetic ataxias are slowly progressing neurodegenerative diseases causing severe disability for which no disease-modifying therapy exists. Though individually they are rare diseases, together they affect nearly 15,000 people worldwide. Current clinical scales for assessment of ataxia severity and progression are ineffective for evaluation of treatment effects during the timeframe of typical clinical trials, necessitating inclusion of high numbers of patients, which often is not feasible, to achieve statistically meaningful outcomes. These challenges could be addressed if reliable, sensitive, and preferably minimally invasive biomarkers for ataxia severity and progression were available for use in clinical trials. Unfortunately, such biomarkers do not presently exist. Therefore, we propose an initial study combining both biomarker discovery using proteomic and transcriptomic approaches, and testing of several promising candidate biomarkers in blood samples from patients with the most common dominant and recessive types of genetically inherited ataxia. We will utilize state-of-the-art techniques including Olink®’s proximity extension proteomics, NextGen RNA sequencing, and electrochemiluminescence immunoassays. The analyses will be done in patient plasma and neuronal extracellular vesicles isolated from the plasma, increasing the likelihood of discovering biomarkers reporting on specific biochemical changes in the central nervous system. The study will generate an initial set of potential biomarkers, providing the basis for subsequent, larger testing and validation in the context of R01 or U01 applications, addressing a current urgent gap in developing effective therapies for patients with genetic ataxias. Additionally, the proteomic and transcriptomic data will allow pathway analysis that may shed new light on the mechanisms underlying the pathogenesis of specific types of genetic ataxia, including both common and distinct features among them.
Grant Summary
Evaluation and discovery of blood-based biomarkers for ataxia is a NINDS - National Institute of Neurological Disorders and Stroke grant providing up to $197K for university, nonprofit, healthcare org. Applications are due 2028-05-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $197K
2028-05-31
- 1Confirm your organization is eligible for Evaluation and discovery of blood-based biomarkers for ataxia from NINDS - National Institute of Neurological Disorders and Stroke, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NINDS - National Institute of Neurological Disorders and Stroke before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NINDS - National Institute of Neurological Disorders and Stroke's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Evaluation and discovery of blood-based biomarkers for ataxia: Frequently Asked Questions
Who is eligible for the Evaluation and discovery of blood-based biomarkers for ataxia?
Evaluation and discovery of blood-based biomarkers for ataxia is offered by NINDS - National Institute of Neurological Disorders and Stroke and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Evaluation and discovery of blood-based biomarkers for ataxia provide?
Evaluation and discovery of blood-based biomarkers for ataxia provides up to $197K per award from NINDS - National Institute of Neurological Disorders and Stroke. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Evaluation and discovery of blood-based biomarkers for ataxia deadline?
Applications for Evaluation and discovery of blood-based biomarkers for ataxia are due 2028-05-31 (open). Because deadlines can change, verify the date with the funder, NINDS - National Institute of Neurological Disorders and Stroke, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Evaluation and discovery of blood-based biomarkers for ataxia?
To apply for Evaluation and discovery of blood-based biomarkers for ataxia, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NINDS - National Institute of Neurological Disorders and Stroke.